Gabapentin Tablet, Film Coated
Product Images NDC 71335-2701

Product Visual Gallery

This gallery contains 7 technical images submitted to the FDA as part of the official labeling for Gabapentin (NDC 71335-2701). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Bryant Ranch Prepack, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Creatinine Clearance (Gabapentin Fig1)

A formula panel showing the equation for calculating creatinine clearance (CLCr). It includes factors of age, weight, serum creatinine, and an adjustment for female patients. The panel is scientific and does not contain product or dosage information.*

FDA Label Image

Figure 1. Weekly Mean Pain Scores (observed Cases In Itt Population): Study 1 (Gabapentin Fig2)

A line graph titled 'Weekly Mean Pain Scores (Observed Cases in ITT Population): Study 1' showing mean pain scores over 8 weeks. It compares pain scores between placebo and Gabapentin 3600 mg/day groups during a 4-week dose titration and a 4-week fixed dose period. Pain scores decrease over time more significantly in the Gabapentin group compared to placebo.*

FDA Label Image

Figure 2. Weekly Mean Pain Scores (observed Cases In Itt Population): Study 2 (Gabapentin Fig3)

A line graph titled 'Weekly Mean Pain Scores (Observed Cases in ITT Population): Study 2' showing mean pain scores over 7 weeks. The x-axis represents weeks, including a 3-week dose titration period and a 4-week fixed dose period. The y-axis measures mean pain score from 0 to 10. The graph compares three groups: Placebo, Gabapentin 1800 mg/day, and Gabapentin 2400 mg/day, illustrating a decrease in pain scores over time for both gabapentin doses compared to placebo.*

FDA Label Image

Figure 3. Proportion Of Responders (patients With ≥50% Reduction In Pain Score) At Endpoint: Controlled Phn Studies (Gabapentin Fig4)

Bar chart depicting the proportion of responders, defined as patients achieving at least 50% reduction in pain score at endpoint, from two controlled postherpetic neuralgia (PHN) studies. The chart compares placebo groups with different Gabapentin dosages, showing higher response rates in Gabapentin groups across both studies. Statistical significance indicators are included for the Gabapentin groups.*

FDA Label Image

Figure 4. Responder Rate In Patients Receiving Gabapentin Expressed As A Difference From Placebo By Dose And Study: Adjunctive Therapy Studies In Patients ≥12 Years Of Age With Partial Seizures (Gabapentin Fig5)

A scatter plot chart showing responder rates in patients receiving Gabapentin as the difference from placebo by dose and study. The vertical axis represents the difference (%) with values from 2 to 22, and the horizontal axis shows daily Gabapentin doses in mg ranging from 600 to 1800. The chart includes data points for three separate studies labeled a, b, and c, distinguishing their respective responder rate differences across the doses.*

FDA Label Image

Chemical Structure (Gabapentin Str)

Chemical structure of Gabapentin showing a cyclohexane ring bonded to amino (CH2NH2) and carboxyl (CH2CO2H) functional groups.*

FDA Label Image

Label (Lbl713352701)

Gabapentin Tablets, USP 600 mg film-coated tablets label with NDC 71335-2701-1 showing package of 30 tablets. The label includes storage instructions, dispensing information, and notes that the product is repackaged by Bryant Ranch Prepack, Inc. and manufactured by Aurobindo Pharma Limited. It features QR codes and barcodes for tracking and package insert access.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.